Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Pharmaceuticals names new head of sales and marketing
Mr Miele will report directly to Ryuji Ueno, chairman and CEO, and will be responsible for Sucampo’s sales and marketing, as well as its business development efforts. Mr
Mr Miele will report directly to Ryuji Ueno, chairman and CEO, and will be responsible for Sucampo’s sales and marketing, as well as its business development efforts. Mr
Under the terms of the transaction, Ipsen paid $9 per outstanding share in cash and the built-in gain in unexercised stock options to acquire the remaining shares of
Existing investors Aisling Capital, L Capital Partners and Pappas Ventures participated in the funding round. CeNeRx plans to use the proceeds to conduct a Phase II clinical trial
Aridol will be distributed in Switzerland by Trimedal, a specialist respiratory and allergy pharmaceutical company based in Zurich, Switzerland. Pricing for Aridol in Switzerland is included under an
The financing, which was led by Bradford Capital Partners, included participation from existing investors led by Kern Whelan Capital. The angel financing provides the company with sufficient capital
The primary objective of this Phase II trial is to evaluate the antidepressant efficacy of Tyrima in patients with confirmed major depressive disorder (MDD). The trial design incorporates
This approval substantially broadens the company’s treatment indications for the Powerlink system, which is used in the minimally invasive treatment of abdominal aortic aneurysms (AAA). The Powerlink XL
Mr Blyth has also been retained as a consultant. In this capacity he will provide strategic guidance in late-stage development and commercialization tactics. Mr Blyth has recently retired
In the trial’s Simon two-stage design, 21 patients with non-small cell lung cancer have been enrolled in Stage A of the study. The trial may be expanded to
The National Surgical Adjuvant Breast and Bowel Project’s (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a